 |
|
|
|
 |
|
|
 Contact |  Print version |  PDF version |  Send article |  RSS-Feed
Anika Therapeutics Announces Termination of Worldwide Development and Commercialization Partnership with OrthoNeutrogena
Company Files Pre-Market Approval Applicaton for Cosmetic Tissue Augmentation Product05 Sep 2005 -
Anika Therapeutics, Inc. announced that it has reached a mutual agreement with OrthoNeutrogena, a division of Ortho-McNeil Pharmaceuticals, for the termination of its development and commercialization contract for Anika's hyaluronic acid based cosmetic tissue augmentation (CTA) product, effective August 31, 2005.
In related news, Anika also announced that, subsequent to such termination, it has filed a pre-market approval application (PMA) with the U.S. Food and Drug Administration for its CTA product and is currently exploring options for its worldwide commercialization.
Additional information
Ortho-McNeil Pharmaceutical, Inc.
South Raritan, NJ, United States of America
News
|
|
|
|
|
|
Top